Sustained-Release PTH 1-34 for Hypoparathyroidism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypoparathyroidism, such as oral calcium and vitamin D supplementation, often fail to improve quality of life and cognitive function, with intermittent administration of PTH 1-84 and PTH 1-34 showing inconsistent results in clinical studies.
Innovation Solution
A sustained-release PTH compound with a release half-life of at least 12 hours, specifically a C-terminally truncated PTH, is used to improve physical and mental well-being in patients with hypoparathyroidism, demonstrating statistically significant improvements in SF-36 functional health and wellbeing outcomes without altering serum calcium levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If intermittent administration of PTH 1-84 and PTH 1-34 is used, then some patients report improved quality of life, but results are inconsistent and not replicated in placebo controlled studies
Solution Approach 1:
The patent employs periodic administration of PTH 1-34 every other day rather than continuous or frequent dosing. This periodic action pattern was found to achieve consistent and reliable improvements in quality of life parameters including mental component scores, physical component scores, and reduction of brain fog symptoms, while maintaining safety and avoiding the inconsistency observed with other intermittent regimens.
2Quantity of substance
If oral calcium and vitamin D supplementation is used, then hypocalcemia is treated, but large amounts are required and long term complications are concerned
Solution Approach 1:
The patent extracts the essential therapeutic function of calcium and vitamin D supplementation by using PTH 1-34, which naturally regulates calcium metabolism. This allows treatment of hypoparathyroidism with much smaller amounts of calcium and vitamin D, reducing the burden on patients and minimizing long term complications associated with high-dose supplementation.
Solution Approach 2:
The patent changes the regulatory parameter from exogenous calcium and vitamin D supplementation to endogenous PTH 1-34 administration. This parameter change enables better control of serum calcium levels, reducing the quantity of calcium and vitamin D needed while eliminating concerns about long term complications from high-dose supplementation.
3Measurement precision
If standard PTH replacement therapy is used, then biochemical control is achieved, but cognitive dysfunction and brain fog persist
Solution Approach 1:
The patent segments the PTH molecule into a truncated form (PTH 1-34) that retains the essential biochemical activity for calcium regulation while potentially providing additional cognitive benefits. This segmentation allows achievement of both biochemical control and improvement in cognitive function, addressing the limitation of standard full-length PTH replacement therapy.
Data Source
AI summary
The present invention relates to a sustained-release PTH compound for use in a method of improving and treating the physical and mental well-being of patients having hypoparathyroidism, wherein the sustained-release PTH compound releases PTH with a release half-life of at least 12 hours. In another aspect the present invention relates to a method of improving physical and mental well-being of a patient having hypoparathyroidism, comprising administering to the patient a sustained-release PTH compound, wherein the sustained release PTH compound releases PTH with a release half-life of at least 12 hours thereby improving physical and mental well-being of the patient.